A mitochondria-targeting Hsp90 inhibitor, gamitrinib, has decreased tumor development and increased mouse survival in subcutaneously and intracranially implanted patient-derived and cell line-derived xenografts—tumor models. This evidence concerns the gene HSP90AB1 and neoplasm.